ORX — Orexo AB Share News
0.000.00%
Last trade - 00:00- SEK850.39m
- SEK471.19m
- SEK26.00m
Brief: Orexo Expects FDA Filing Of OX124 Mid 2022
Brief: Orexo Q4 EBITDA Slumps To SEK 1.0 Mln
Brief: Orexo Strengthens IP Rights For Overdose Rescue Drug OX124
Brief: Orexo Announces New Us Patent For Zubsolv
Advisory: Multiple dated alerts withdrawn
Brief: Orexo Signs License And Supply Deal With Accord Healthcare
Brief: Orexo Q3 EBITDA Ex-Items Falls To Sek 50.3 Mln
Brief: Orexo Commences Patent Infringement Litigation Against Sun Pharmaceutical
Brief: Orexo Receives Paragraph IV Notice Letter For In The US
Brief: Orexo Q2 EBITDA Swings To Loss SEK 9.0 Mln
Brief: Orexo Launches Deprexis And Vorvida In The U.S. And Provides Updated Financial Guidance
Brief: Orexo Raises FY OPEX Guidance To Reflect US Launches Of Deprexis And Vorvida
Brief: Positive Results From Human PK Study Assessing Orexo's Intranasal Nalmefene Formulations For Opioid Overdose Reversal
Brief: Orexo Partners With Lyfebulb
Brief: Orexo: Gesynta Pharma Announces Positive Results From Phase 1 Study For OX-MPI
Brief: Orexo Acquires Exclusive U.S. Rights To Commercialize Deprexis
Brief: Orexo Q1 EBITDA Up At SEK 39.1 Mln
Brief: Orexo AB Says Board Withdraws Proposal On Incentive Program
Brief: Orexo Ends Share Buy-Back Program